Astellas Pharma vs. Apsen: Appeal Dismissed in Mirabegron Patent Case in São Paulo
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Astellas Pharma, Inc. v. Apsen Farmacêutica S.A. |
| Case Number | 2131917-74.2024.8.26.0000 |
| Court | Court of Justice of São Paulo, Brazil |
| Appeal Dismissed | August 21, 2024 |
| Outcome | Plaintiff Win — Appeal Dismissed |
| Patents at Issue | |
| Accused Products | Apsen’s Mirabegron Generic Product (allegedly infringing MYRBETRIC®) |
Case Overview
The Parties
⚖️ Plaintiff
Tokyo-headquartered global pharmaceutical company with a substantial IP portfolio spanning urology, oncology, and transplantation therapeutics. Holder of patent BRPI0213570B1.
🛡️ Defendant
Well-established Brazilian pharmaceutical company with a strong presence in the domestic generics and branded generics market.
The Patent at Issue
This case centered on **BRPI0213570B1**, a Brazilian patent corresponding to Astellas’s proprietary mirabegron compound technology. Mirabegron operates as a beta-3 adrenergic receptor agonist—a mechanism of action distinct from traditional anticholinergic OAB treatments—and represents a significant therapeutic advance. The patent protects core formulation and/or compound aspects of this technology in Brazil.
- • BRPI0213570B1 — Mirabegron compound technology for overactive bladder
Developing a Mirabegron-based Product?
Check if your pharmaceutical formulation might infringe this or related patents before launch.
The Verdict & Legal Analysis
Outcome
The Court of Justice of São Paulo ruled unequivocally: “The claim of the present appeal is denied.” The appeal was dismissed in its entirety, reinforcing Astellas’s IP position in Brazil. No specific damages amount was disclosed, consistent with the appellate procedural posture where the court was reviewing, rather than reassessing, underlying infringement determinations.
Key Legal Issues
The Court of Justice of São Paulo’s dismissal of the appeal indicates that Apsen failed to persuade the appellate panel that reversible legal or factual errors occurred in the underlying proceedings. Brazilian appellate courts apply a structured review standard—appellants must demonstrate specific grounds for reversal. The clean dismissal here suggests the appellate arguments did not meet this threshold.
While the specific legal reasoning of the panel was not detailed in the provided case data, the outcome is consistent with Brazilian courts’ increasing rigor in evaluating pharmaceutical patent challenges. Brazil’s IP legal framework under Lei No. 9.279/96 (Industrial Property Law) provides robust protection for validly granted patents, and the INPI’s examination process has yielded patents that Brazilian courts have demonstrated willingness to enforce.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in mirabegron development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this pharmaceutical litigation.
- View all related patents for mirabegron technology
- See which companies are most active in beta-3 agonist IP
- Understand claim construction patterns relevant to pharma
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your mirabegron formulation or related technology.
- Input your formulation details or technical features
- AI identifies potentially blocking patents (e.g., BRPI0213570B1)
- Get actionable risk assessment report for Brazil
High Risk Area
Mirabegron Formulations & Derivatives
1 Patent at Issue
BRPI0213570B1
Design-Around Options
Available, but challenging for core compounds
✅ Key Takeaways
Brazilian appellate courts show rigor in pharmaceutical IP disputes, often upholding lower court infringement rulings.
Search related case law →Appeal strategies in Brazilian IP cases must introduce distinct legal arguments—rearticulation of first-instance positions carries high dismissal risk.
Explore precedents →Consider parallel INPI nullity proceedings as an important tactical option for patent challengers operating alongside court litigation.
Learn about INPI proceedings →Frequently Asked Questions
The case involved Brazilian patent BRPI0213570B1, covering mirabegron-related technology, which protects Astellas’s MYRBETRIC® overactive bladder treatment in Brazil.
The Court of Justice of São Paulo denied the appeal in its entirety (Case No. 2131917-74.2024.8.26.0000), concluding on August 21, 2024. The appeal was dismissed without reversal of the underlying infringement action outcome.
The ruling reinforces Brazilian appellate courts’ willingness to uphold pharmaceutical patent enforcement, strengthening originator companies’ litigation posture and raising the strategic bar for generic challengers pursuing appellate remedies.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- Court of Justice of São Paulo (Tribunal de Justiça do Estado de São Paulo) — Case 2131917-74.2024.8.26.0000
- Brazilian National Institute of Industrial Property (INPI) — Patent Database
- Brazilian Industrial Property Law (Lei No. 9.279/96)
- World Intellectual Property Organization (WIPO) — Patent Resources
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.